
https://www.science.org/content/blog-post/another-ai-drug-announcement
# Another AI Drug Announcement (December 2021)

## 1. SUMMARY

The article critiques InSilico Medicine's announcement of ISM001-055, a purportedly AI-developed drug candidate for idiopathic pulmonary fibrosis (IPF) that had advanced to human clinical trials. The author notes two AI claims: discovery of a new compound and identification of a new antifibrotic target, likely TRAF2 and NCK-interacting protein kinase (TNIK), primarily based on analysis of patent applications rather than explicit company disclosure.

The author provides measured analysis of InSilico's approach, which used the PandaOmics platform for target discovery (analyzing patents, publications, grants, and clinical trial databases) and the Chemistry42 engine for compound generation. While acknowledging this represents progress over previous AI-drug hype, the author highlights key limitations: TNIK already had literature backing as a plausible target (primarily in colorectal cancer research), the fundamental mechanisms of IPF remain unknown, and no biological "derisking" has occurred. The chemical matter involves novel imidazole compounds with potential selectivity issues against MAP4K4. The assessment concludes this is a step forward but cautions against overstating the breakthrough, emphasizing that meaningful AI impact in drug discovery remains a challenging, ongoing journey rather than a sudden revolution.

## 2. HISTORY

Following the December 2021 announcement and the article's publication, InSilico Medicine's ISM001-055 progressed through clinical development with notable milestones:

**Clinical Trial Progress**: The compound advanced through Phase 1 clinical trials, demonstrating acceptable safety profiles. InSilico Medicine reported positive results in healthy volunteers and began exploring the drug in IPF patients.

**Broader Pipeline Development**: Beyond ISM001-055, InSilico Medicine expanded its AI-driven pipeline significantly. The company advanced multiple additional candidates into clinical trials across different therapeutic areas, including oncology and immunology, demonstrating the scalability of their Pharma.AI platform approach.

**Industry Validation and Partnerships**: InSilico Medicine secured significant partnerships and funding, including collaborations with pharmaceutical companies and substantial investment rounds that valued the company at over $1 billion by 2022-2023, indicating industry confidence in their AI drug discovery approach.

**Regulatory Recognition**: The company's AI-driven approach gained regulatory acceptance, with multiple investigational new drug (IND) applications approved by regulatory agencies including the FDA and agencies in China, validating the acceptability of AI-discovered compounds for clinical development.

**Target Validation**: While TNIK remained a relatively underexplored target, subsequent research continued to explore its role in fibrosis and other disease pathways, though no major breakthrough publications radically changed the understanding of TNIK's therapeutic potential beyond the existing literature referenced in the original article.

**IPF Treatment Landscape**: The broader IPF treatment landscape evolved modestly, with pirfenidone and nintedanib remaining the standard-of-care medications, though new mechanisms continued to be explored in clinical trials. No radically superior therapies emerged that would displace these established treatments.

## 3. PREDICTIONS

**Prediction: "I definitely wish InSilico and their partners luck with this one - at the very least, the world needs another fibrosis drug."**
- **Outcome**: This generally positive sentiment aligned with continued development of ISM001-055 through clinical trials, though no FDA approval has been announced as of early 2024. The drug candidate progressed but has not yet reached market approval or widespread patient use. The fundamental need for better fibrosis treatments remains unmet by breakaway successes.

**Prediction: "But don't imagine that the Brave New World has quite dawned yet. That doesn't mean it won't, and it certainly doesn't mean it can't, but it's going to be a hard road and we're still traveling down it."**
- **Outcome**: The prediction proved accurate. While InSilico Medicine and other AI drug discovery companies (such as Exscientia, Recursion Pharmaceuticals, and others) advanced multiple candidates into clinical trials, no AI-discovered drug achieved blockbuster status or obvious transformative impact on medicine by early 2024. The field continued progressing incrementally rather than experiencing sudden revolutionary breakthroughs. AI drug discovery remained an active, challenging area with gradual rather than dramatic success.

**Implicit Prediction (Author skepticism about AI claims of novelty and breakthrough impact)**: 
- **Outcome**: The measured assessment proved appropriate. While InSilico Medicine demonstrated progress with multiple candidates advancing through trials, subsequent developments did not reveal radical biological insights or unambiguously novel mechanisms that would fundamentally change disease understanding, consistent with the author's caution about AI limitations in addressing higher-level biological questions.

## 4. INTEREST

Rating: **7/10**

This article warrants a 7/10 rating because it provides well-reasoned, technically grounded analysis of AI drug discovery at a time of significant industry hype, offering balanced perspective on both progress and limitations. The author's specific technical insights (about TNIK as a target, chemical matter analysis, and realistic assessment of AI capabilities) demonstrate domain expertise and provide lasting analytical value for understanding the evolution of computational drug discovery approaches. The article's measured tone and evidence-based skepticism represent a valuable counterpoint to promotional narratives while acknowledging genuine advances.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20211209-another-ai-drug-announcement.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_